secwatch.observer — SEC 8-K summary
======================================

Issuer:     OCULAR THERAPEUTIX, INC (OCUL)
CIK:        0001393434
Form:       8-K
Filed at:   2022-02-28T23:59:59+00:00
Accession:  0001104659-22-028082
Event type: earnings
Sentiment:  positive
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Ocular Therapeutix reports Q4 2021 DEXTENZA revenue $12.2M, up 77% YoY; net loss $3.9M
--------------------------------------------------------------------------------

- DEXTENZA net product revenue $12.2M in Q4, +77% vs Q4 2020; full year $43.5M vs $17.4M.
- Net loss $(3.9)M ($0.05 basic EPS) includes $15.9M non-cash gain; full year net loss $(6.6)M.
- Cash $164.2M at Dec 31, 2021; expects to fund operations through 2023.
- OTX-TKI (wet AMD) US Phase 1 fully enrolled; interim data expected H2 2022.
- OTX-DED (dry eye) Phase 2 met primary endpoint; positive top-line data Dec 2021.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1393434/000110465922028082/0001104659-22-028082-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1393434/000110465922028082/tm227780d2_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-22-028082

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer